NCT07527195

Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Cagrilintide	Participants will receive cagrilintide subcutaneously.
DRUG	Semaglutide	Participants will receive semaglutide subcutaneously.
DRUG	Placebo cagrilintide	Participants will receive placebo matched to cagrilintide subcutaneously.
DRUG	Placebo semaglutide	Participants will receive placebo matched to semaglutide subcutaneously.

Timeline

• Start date: 2026-04-10
• Primary completion: 2028-04-28
• Completion: 2028-06-09
• First posted: 2026-04-14
• Last updated: 2026-04-14

Locations

1 site across 1 country: Denmark

Regulatory

• FDA-regulated drug study